Alto Neuroscience (ANRO)

• Market cap: $111M
• 1 day: 7.59%
• 5 days: 4.85%
• 1 month: 20.53%
• 3 months: 81.06%
• 6 months: 42.71%
• Year to date: -6.16%
• 1 year: -68.86%
• 5 years: -80.14%
• 10 years: -80.14%
• Sector: Healthcare
• Industry: Biotechnology

About: Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.

Employees: 76

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

9% less repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 23

5% less funds holding

Funds holding: 83 [Q1] → 79 (-4) [Q2]

13.12% less ownership

Funds ownership: 77.01% [Q1] → 63.89% (-13.12%) [Q2]

15% less capital invested

Capital invested by funds: $45M [Q1] → $38.1M (-$6.98M) [Q2]

17% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 23

50% less funds holding in top 10

Funds holding in top 10: 2 [Q1] → 1 (-1) [Q2]

75% less call options, than puts

Call options by funds: $11K | Put options by funds: $44K

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $10
• Avg. target: $10
• High target: $10

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Patrick R. Trucchio	$10	Buy Reiterated	18 Aug 2025
HC Wainwright & Co. Patrick Trucchio	$10	Buy Reiterated	26 Jun 2025